KCI negative pressure wound therapy qualifies for drug tariff

KCI's next-generation negative pressure wound therapy (NPWT) solution VAC Via has been accepted for listing on the UK drug tariff.

As of August 1st 2011, the treatment system will be granted reimbursement status, meaning NHS clinicians and patients will be able to benefit from its use in a more cost-effective manner.

VAC Via is a portable, discreet and intuitive NPWT system that utilises Vortis technology and is designed for the treatment of low- to moderate-exudating wounds.

Thanks to its compact nature, it can be easily used in the home, which is a key priority in the Department of Health's strategy for encouraging home-based treatments that can save money for hospitals and the NHS.

Mike Genau, global president of KCI's Active Healing Solutions business unit, said: "The economic benefits … are clear: patients are able to leave the hospital in a quicker and more seamless manner by eliminating waiting in the hospital just for therapy to arrive."

Last month, the company announced that it will be launching a Transcontinental Wound Registry for associated healing and care technologies, in partnership with the Academy of Wound Technology.